Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001127 · ClinicalTrials.gov registry record · Phase 3
Study of a Flu Vaccine in Children
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 15,000
- Enrollment target
NCT00001127: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001127 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 15,000 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1846% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001127, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15,000 participants
- Enrollment target
Study Summary
This study tests the safety and effectiveness of a flu vaccine in school children. School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu vaccine can help prevent the spread of the flu to other members of the community.
Interventions
- BIOLOGICAL Influenza virus vaccine (CAIV-T)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00001127 record still lists
NCT00001127 is an interventional study that assigns participants to a tested intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1846% higher).
The record links to 0 conditions, and to 1 intervention - of which Influenza virus vaccine (CAIV-T) is the first listed.
NCT00001127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001127 about?
NCT00001127 is a clinical study titled "Study of a Flu Vaccine in Children". This study tests the safety and effectiveness of a flu vaccine in school children. School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu ...
What is the current status of trial NCT00001127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15,000 participants. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00001127?
The interventions under investigation include: Influenza virus vaccine (CAIV-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001127?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00001127's enrollment target sits among peer trials
15,000 14th of 2000 higher than 1,986 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment